LDN Social Media
Get connected with us on social networks
How to treat pathologic cell behaviors - Mark Cooper, PhD (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)
Chronic neuroinflammation involves pathogenic cell behaviors. Aberrant epigenetics underlie these behaviors. The reason to examine them is to understand the actions of therapeutics, like low dose naltrexone and high dose vitamin D, as a means of altering the trajectory of the inflamed nervous system. He discusses the suppression of aberrant cell behaviors using therapeutics such as low dose naltrexone and high dose vitamin D, by acting on Toll-like receptors.
Dr. Cooper explains the role of various receptors such as Toll and vitamin D receptors by explaining wound closure. Associated neuro injury results in the activation of microglia - neuroimmune activation - and Toll-like receptors are key players in microglial activation. He discusses suppression of ACE, M1 macrophage phenotype, activation of VDR and the ACE2 pathway, and neuroinflammatory conditions such as dystonia, autoimmune encephalitis as a consequence of autoantibodies. Autoimmune conditions are often triggered by an ongoing or antecedent infectious agent, perhaps a virus, bacterium, or protozoan. There are structural changes in the brain, as well as functional changes.
Dr. Cooper talks about the epigenetics of neuroinflammation: pathologic cell behaviors, and the intracellular machinery which drives them. Using slides, he explains 10 pathogenic modules that are drivers of neuroinflammation, with links to the literature.
LDN is a glial attenuator that can bind to TLRs and other receptors, and target tissues that are inflamed by the neurogenic actions of a hyperactive immune state. It can attenuate mast cell activity and attenuate endothelial cell responses. A combination of therapeutic agents can be used to inhibit the survival of pathogenic plasma cells, which can survive for years producing pathogenic autoantibodies.
He encourages viewers to consult the LDN Research Trust literature and PubMed, and the experience of practitioners who are skilled in the use of these therapeutics.
KEYWORDS: neuroinflammation, autoantibodies, receptors, low dose naltrexone, LDN, microglia, vitamin D, epigenetics, movement disorder, CPRS, dystonia, encephalitis, MS, vitiligo, psoriasis
This is a summary of the presentation. Watch the video for full information.